Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes

I. V. Kononenko; O. M. Smirnova

Meditsinskiy sovet = Medical Council
Meditsinskiy sovet

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)

User

eng | рус

Meditsinskiy sovet = Medical Council

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Kononenko IV, Smirnova OM. Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes. Meditsinskiy sovet = Medical Council. 2024;(13):138-145. (In Russ.) https://doi.org/10.21518/ms2024-256

Views PDF (Rus): 193

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)

Editor-in-Chief

Aydar A. Ishmukhametov

* not an advertisement

По рекомендации Президиума ВАК от 8 декабря 2023 г. № 31/1-разн

"О категорировании перечня рецензируемых научных изданий, в которых должны быть опубликованы основные научные результаты диссертаций на соискание ученой степени кандидата наук, на соискание ученой степени доктора наук" журналу «Медицинский совет» присвоена категория К1

Popular articles

Indexing Databases

* not an advertisement

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

I. V. Kononenko
Endocrinology Research Centre
Russian Federation

Irina V. Kononenko - Cand. Sci. (Med.), Associate Professor of the Department of Diabetology and Dietetics of the Institute of Higher and Further Professional Education, Endocrinology Research Centre.

11, Dmitry Ulyanov St., Moscow, 117036

O. M. Smirnova
Endocrinology Research Centre
Russian Federation

Olga M. Smirnova - Dr. Sci. (Med.), Professor, Endocrinology Research Centre.

11, Dmitry Ulyanov St., Moscow, 117036

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Meditsinskiy sovet = Medical Council

For citations:

Cookies policy